Novo Nordisk Makes $9B Bid for Obesity-Drug Developer Metsera
Novo Nordisk is launching an unsolicited bid to acquire obesity-drug developer Metsera. The Danish pharmaceutical company, known for blockbusters like Ozempic and Wegovy, offers $56.50 per share in cash with the potential for another $21.25 if certain milestones are reached. This deal could potentially top Pfizer’s previous offer of the same value. A legal battle … Read more